Intrasense (ISIN : FR0011179886 – Mnémo : ALINS), the French expert in AI-enhanced medical imaging solutions that facilitate and secure diagnosis, decision-making and therapeutic follow-up, announces that it has obtained CE marking under MDR (Medical Device Regulation) for Myrian^® 2.14, the new version of its advanced radiology visualization solution. This new CE marking for Intrasense's innovative solutions is fully in line with the Group's strategic roadmap, based on four pillars: innovation, product range extension, geographical expansion and financial control.

Intrasense (ISIN : FR0011179886), a French expert in medical imaging solutions facilitating diagnosis, decision-making, and therapeutic follow-up, announces the publication of its 2024 annual results and its new strategic roadmap. These financial statements were approved on March 25, 2025, by the Board of Directors. The audit procedures on the consolidated accounts have been completed, and the certification report was issued on March 26 by the statutory auditors.

Guerbet (FR0000032526 GBT), a world leader in medical imaging solutions, today announced that the US Food and Drug Administration (FDA) has granted “Breakthrough Device” designation to DUOnco^TM Pancreas for which Intrasense (ISIN: FR0011179886 - Mnemo: ALINS), a French expert in AI-enhanced medical imaging solutions facilitating and securing diagnosis, decision-making and therapeutic follow-up, will be the legal manufacturer.

Montpellier, France, march 18, 2025. Intrasense (ISIN : FR0011179886 – Mnémo : ALINS), French expert in medical imaging solutions enhanced by AI assisting and securing diagnosis, decision-making and therapeutic follow-up, and Guerbet (FR0000032526 GBT), worldwide leader in medical imaging, and Intrasense (FR0011179886 - ALINS), announces the CE marking under MDR (Medical Device Regulation) DUOnco™ Bone, an innovate solution in IA, the world's first dedicated IA to the detection and localization of bone lesions on thoraco-abdomino-pelvic (TAP) scans.

Intrasense (ISIN: FR0011179886), French expert in medical imaging solutions to assist and secure diagnosis, decision-making and therapeutic follow-up, announces the publication of its financial calendar for fiscal year 2025.

Intrasense (ISIN: FR0011179886 – Mnémo : ALINS), French expert in medical imaging solutions enhanced by AI assisting and securing diagnosis, decision-making and therapeutic follow-up, took part in the Side Event AI Action Summit, an event held on February 11, 2025 at the Grand Palais in Paris, as part of AI Action Week.

Intrasense (ISIN: FR0011179886 - Mnemo: ALINS), a French expert in AI-enhanced medical imaging solutions facilitating and securing diagnosis, decision-making and therapeutic follow-up, publishes its consolidated sales for the full year 2024.

Montpellier, France, February 3, 2025. Intrasense (ISIN: FR0011179886 – Mnémo : ALINS), French expert in medical imaging solutions enhanced by AI assisting and securing diagnosis, decision-making and therapeutic follow-up, announces its participation in the European Congress of Radiology (ECR) 2025, which will take place between February 26 and March 2 in Vienna (Austria).

Intrasense (ISIN: FR0011179886), French expert in medical imaging solutions to assist and secure diagnosis, decision-making and therapeutic follow-up, announces the publication of its financial calendar for fiscal year 2025.

Intrasense (FR0011179886 - ALINS), medical imaging software solutions expert and developer of Myrian® et Liflow®, is proud to announce that the Lilfow® solution obtained the CE certification under MDR1, integrating a new AI algorithm for the detection of focal liver lesions developed in collaboration with Guerbet (trade name: DUOnco™ Liver). This new version is being deployed on clinical sites.